David Hallal - Oct 19, 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role
Director, 10%+ Owner
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Stock symbol
ALVR
Transactions as of
Oct 19, 2022
Transactions value $
-$5,070,000
Form type
4
Date filed
10/21/2022, 09:30 PM
Previous filing
Sep 30, 2022
Next filing
May 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Sale -$5.07M -600K -81.28% $8.45 138K Oct 19, 2022 See Footnote F1
holding ALVR Common Stock 2.07M Oct 19, 2022 Direct
holding ALVR Common Stock 721K Oct 19, 2022 See Footnote F2
holding ALVR Common Stock 16.7M Oct 19, 2022 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Terrie A. Hallal Family Irrevocable Trust 2012, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2 Shares held by The Hallal Family Irrevocable Trust 2012, for which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is the Chairman and Chief Executive Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.